Upgrade to SI Premium - Free Trial

Karyopharm Therapeutics (KPTI)

9.08 +0.01 (0.11%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: T. Rowe Price Investment Management, Inc. June 5, 2026 11:43 AM - SEC Filing Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 June 3, 2026 4:15 PM - PR NewsWire Karyopharm cancer trial selected for late-breaking presentation at EHA June 2, 2026 10:03 AM - StreetInsider Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026 June 2, 2026 10:03 AM - PR NewsWire Karyopharm presents phase 3 trial results at ASCO 2026 June 2, 2026 9:00 AM - StreetInsider Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of C June 2, 2026 9:00 AM - PR NewsWire Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 1, 2026 4:05 PM - PR NewsWire Karyopharm schedules investor call on myelofibrosis trial results June 1, 2026 7:30 AM - StreetInsider Karyopharm to Host Investor Conference Call Featuring Expert Perspectives on the Phase 3 SENTRY Trial in Myelofibrosis Following 2026 ASCO Presentation June 1, 2026 7:30 AM - PR NewsWire Form 8-K Karyopharm Therapeutics For: May 21 May 28, 2026 5:01 PM - SEC Filing Karyopharm to Participate at the 2026 Jefferies Global Healthcare Conference May 28, 2026 7:30 AM - PR NewsWire Form S-8 Karyopharm Therapeutics May 27, 2026 5:00 PM - SEC Filing Form S-8 Karyopharm Therapeutics May 27, 2026 4:59 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: Oliger Christy J. May 26, 2026 4:31 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: PAKIANATHAN DEEPIKA May 26, 2026 4:27 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: Schor Chen May 26, 2026 4:25 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: Su Zhen May 26, 2026 4:23 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: BOHLIN GAREN G May 26, 2026 4:20 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 21 Filed by: Greene Barry E May 26, 2026 4:15 PM - SEC Filing Form SCHEDULE 13G Karyopharm Therapeutics Filed by: Ikarian Capital, LLC May 15, 2026 5:04 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Poulton Stuart May 15, 2026 4:14 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Rangwala Reshma May 15, 2026 4:13 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Cheng Sohanya Roshan May 15, 2026 4:10 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Abate Kristin May 15, 2026 4:07 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Paulson Richard A. May 15, 2026 4:06 PM - SEC Filing Form 4 Karyopharm Therapeutics For: May 13 Filed by: Mano Michael May 15, 2026 4:05 PM - SEC Filing Form SCHEDULE 13G Karyopharm Therapeutics Filed by: ACORN BIOVENTURES, L.P. May 15, 2026 2:59 PM - SEC Filing Form EFFECT Karyopharm Therapeutics May 15, 2026 6:35 AM - SEC Filing Form EFFECT Karyopharm Therapeutics May 15, 2026 6:35 AM - SEC Filing Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Affinity Asset Advisors, LLC May 14, 2026 4:07 PM - SEC Filing Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 124c May 14, 2026 7:52 AM - StreetInsider Form 10-Q Karyopharm Therapeutics For: Mar 31 May 14, 2026 7:46 AM - SEC Filing Form 8-K Karyopharm Therapeutics For: May 14 May 14, 2026 7:32 AM - SEC Filing Karyopharm completes endometrial cancer trial enrollment, reports Q1 revenue May 14, 2026 7:30 AM - StreetInsider Karyopharm reports Q1 revenue up 17% as endometrial cancer study completes May 14, 2026 7:30 AM - StreetInsider Karyopharm completes endometrial cancer trial enrollment, reports Q1 results May 14, 2026 7:30 AM - StreetInsider Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment May 14, 2026 7:30 AM - PR NewsWire Form SCHEDULE 13G Karyopharm Therapeutics Filed by: Adage Capital Management, L.P. May 13, 2026 9:23 AM - SEC Filing Form SCHEDULE 13G Karyopharm Therapeutics Filed by: GOLDMAN SACHS GROUP INC May 12, 2026 3:58 PM - SEC Filing Intellia short interest rises most among biotech stocks in latest period - Baird May 12, 2026 9:58 AM - StreetInsider Karyopharm to Participate at Upcoming Investor Conferences May 12, 2026 7:30 AM - PR NewsWire Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: Opaleye Management Inc. May 11, 2026 4:23 PM - SEC Filing Karyopharm to Report First Quarter 2026 Financial Results on May 14, 2026 May 7, 2026 7:30 AM - PR NewsWire Karyopharm Therapeutics (KPTI) PT Raised to $13 at H.C. Wainwright May 6, 2026 7:04 AM - StreetInsider Karyopharm Therapeutics (KPTI) files for 8.84M share offering by selling stockholders May 4, 2026 4:41 PM - StreetInsider Karyopharm Therapeutics (KPTI) files $400M mixed shelf May 4, 2026 4:38 PM - StreetInsider Form S-3 Karyopharm Therapeutics May 4, 2026 4:38 PM - SEC Filing Form S-3 Karyopharm Therapeutics May 4, 2026 4:37 PM - SEC Filing Karyopharm Therapeutics (KPTI) PT Lowered to $8 at Piper Sandler April 27, 2026 9:36 AM - StreetInsider Form 4 Karyopharm Therapeutics For: Apr 21 Filed by: Rangwala Reshma April 22, 2026 4:04 PM - SEC Filing KPTI phase 3 myelofibrosis trial selected for ASCO presentation April 21, 2026 10:33 AM - StreetInsider Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting April 21, 2026 10:33 AM - PR NewsWire Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: INTEGRATED CORE STRATEGIES (US) LLC April 13, 2026 5:29 PM - SEC Filing Form ARS Karyopharm Therapeutics For: Dec 31 April 13, 2026 8:25 AM - SEC Filing Form DEF 14A Karyopharm Therapeutics For: Apr 13 April 13, 2026 8:23 AM - SEC Filing Karyopharm Therapeutics (KPTI) PT Lowered to $16 at RBC Capital April 7, 2026 9:02 AM - StreetInsider Form SCHEDULE 13G Karyopharm Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P. April 2, 2026 4:47 PM - SEC Filing Form SCHEDULE 13G Karyopharm Therapeutics Filed by: Commodore Capital LP April 2, 2026 4:26 PM - SEC Filing Karyopharm Therapeutics (KPTI) PT Lowered to $8 at Piper Sandler March 30, 2026 9:04 AM - StreetInsider Form 8-K Karyopharm Therapeutics For: Mar 27 March 27, 2026 8:04 AM - SEC Filing Karyopharm Therapeutics (KPTI) PT Lowered to $15 at Baird March 25, 2026 7:18 AM - StreetInsider Karyopharm Therapeutics (KPTI) PT Lowered to $8 at H.C. Wainwright March 25, 2026 6:54 AM - StreetInsider Karyopharm Therapeutics (KPTI) PT Lowered to $5 at Leerink Partners March 24, 2026 2:52 PM - StreetInsider Karyopharm Therapeutics (KPTI) PT Lowered to $14 at Jefferies March 24, 2026 1:40 PM - StreetInsider Increasing unusual option volume: KPTI TWO EWT CDNS DBA ORBS ACHV BOX March 24, 2026 10:35 AM - StreetInsider RBC Capital defends Karyopharm Therapeutics (KPTI) amid 10pct premarket drop: 'We see upside potential' March 24, 2026 9:19 AM - StreetInsider Form 8-K Karyopharm Therapeutics For: Mar 24 March 24, 2026 8:01 AM - SEC Filing Karyopharm Therapeutics (KPTI) to resume trading at 7:30 am March 24, 2026 7:18 AM - StreetInsider Karyopharm raises $30 million in private placement with RA Capital March 24, 2026 7:02 AM - StreetInsider Karyopharm Announces $30 Million Private Placement with RA Capital March 24, 2026 7:02 AM - PR NewsWire Karyopharm's myelofibrosis drug trial meets one of two primary goals March 24, 2026 7:01 AM - StreetInsider Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Met First Co-Primary Endpoint, Demonstrating Statistically Significant Improvement in Spleen Volume Reduction March 24, 2026 7:00 AM - PR NewsWire Karyopharm Therapeutics (KPTI) Halted, News Pending March 24, 2026 6:57 AM - StreetInsider Karyopharm Therapeutics (KPTI) March 10 puts, April 10 puts, April 10 calls and April 17.50 calls active March 23, 2026 4:52 AM - StreetInsider Increasing unusual call option volume: TME ORBS VSAT AIRS SMTC JBL SCO KPTI March 18, 2026 5:56 AM - StreetInsider Increasing unusual put option volume: LW FXE BAM YOU TSEM LWLG COMP BIZD CWVX KPTI March 16, 2026 10:41 AM - StreetInsider Rodman & Renshaw Starts Karyopharm Therapeutics (KPTI) at Buy, PT $28 March 9, 2026 4:16 PM - StreetInsider Full Article List